GLIADEL Implant is indicated for the treatment of adult patients with newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. GLIADEL Implant is indicated as an adjunct to surgery for the treatment of adult patients with recurrent histologically proved glioblastoma multiforme and for whom surgical resection is indicated.
Retina Implant AG has announced the publication of data from the Company's global clinical trial involving seven sites across five...
Retina Implant AG's wireless subretinal implant technology, the Alpha IMS, has received CE Mark approval in the EU to treat...
Intarcia Therapeutics, Inc., announced that the FDA has issued a Complete Response Letter (CRL) for ITCA 650 (exenatide implant) for...
Two patients in a UK trial of the retinal implant, from Retina Implant AG, to treat Retinitis Pigmentosa have regained...
Retina Implant has announced that Dr. Helmut Sachs, senior consultant and head of the Department of Ophthalmology, Clinic Dresden-Friedrichstadt, Germany...
Smith & Nephew the global medical technology business, announced the launch of its Legion HK Hinge Knee implant to surgeons...
Titan Pharmaceuticals, Inc. announced that the FDA has approved Probuphine (buprenorphine) implant, the first product for the long-term maintenance treatment...
Braeburn Pharmaceuticals announces data from the Phase III study of Probuphine, a six month subdermal buprenorphine implant for the long-term...